Positron emission tomography: Applications in drug discovery and drug development

被引:79
|
作者
Wang, JL [1 ]
Maurer, L [1 ]
机构
[1] ALZA Corp, Mountain View, CA 94040 USA
关键词
positron emission tomography; microPET; molecular imaging;
D O I
10.2174/156802605774297056
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Positron Emission Tomography (PET) is a sophisticated nuclear imaging modality that affords researchers the ability to conduct both functional and molecular imaging on biological and biochemical processes in vivo. In functional imaging, biological parameters such as metabolic rate and perfusion that can be altered by disease or treatment are monitored. In molecular imaging, PET can be used to examine and quantify cellular events such as cell trafficking, receptor binding and gene expression. Therefore, PET is an important tool to elucidate mechanisms associated with diseases and drug actions. In addition to PET, microPET is designed to image small animals. A great tool to facilitate preclinical studies and basic research, it can eliminate the need of sacrificing the animal by enabling noninvasive, longitudinal, and serial studies. The results from preclinical studies using microPET can be directly correlated with clinical studies using PET, thus bridging the chasm that used to separate the 2 pivotal phases in drug development. This review first describes the basic principles of PET and compares it to other imaging modalities. Then, PET procedures and PET isotopes and tracers synthesis are outlined. Next, functional and molecular PET imaging applications in the fields of oncology, neurology, and cardiology in both humans and animals are presented. Spanning a wide range, these applications demonstrate the versatility of PET and how it can be used to accelerate drug discovery and development. Finally, the advantages and limitations of PET and how it can be used in the future to minimize risks of drug development are discussed.
引用
收藏
页码:1053 / 1075
页数:23
相关论文
共 50 条
  • [1] Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring
    Piel, Markus
    Vernaleken, Ingo
    Roesch, Frank
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (22) : 9232 - 9258
  • [2] Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
    Miller, Jeffrey M.
    Kumar, Dileep
    Mann, J. John
    Parsey, Ramin V.
    CURRENT RADIOPHARMACEUTICALS, 2008, 1 (01) : 12 - 16
  • [3] Fundamentals of positron emission tomography and applications in preclinical drug development
    Cherry, SR
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (05): : 482 - 491
  • [4] Positron emission tomography in drug development and drug evaluation
    Paans, AMJ
    Vaalburg, W
    CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (16) : 1583 - 1591
  • [5] Positron emission tomography in central nervous system drug discovery and development
    Cooper, M
    Metz, J
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2003, 13 (04) : 851 - +
  • [6] Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development
    Burns, HD
    Hamill, TG
    Eng, W
    Francis, B
    Fioravanti, C
    Gibson, RE
    CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) : 388 - 394
  • [7] Positron emission tomography in serotonergic drug development
    Andrée, B
    JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (01) : 90 - 91
  • [8] Positron emission tomography agents for central nervous system drug development applications
    Mason, NS
    Mathis, CA
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 49 - 68
  • [9] Positron emission tomography molecular imaging for drug development
    Matthews, Paul M.
    Rabiner, Eugenii A.
    Passchier, Jan
    Gunn, Roger N.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 175 - 186
  • [10] Use of positron emission tomography in anticancer drug development
    Aboagye, EO
    Price, PM
    INVESTIGATIONAL NEW DRUGS, 2003, 21 (02) : 169 - 181